PATENT CLAIM ANALYSIS

Application Number: 15976630
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-10
Patent Classification: ["424", "278100"]

Abstract:
Provided herein are novel therapeutic compositions and methods that keep cellular immunotherapies in the circulation or at the site of injection for extended periods of time without resorting to the use of cytotoxic preconditioning. More specifically the compositions and methods herein lymphodeplete and reduce or ablate sites in the secondary lymphatics where the cellular immunotherapy is bound and sequestered, without the use of cytotoxic preconditioning.

Claim (Index 12):
The method according to  claim 1 , wherein the enhanced ACT comprises enhanced cancer killing, reduced autoimmune causing cell count, or reduced infectious agent load in a patient with a cancer, autoimmune or infectious disease, respectively.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 93.0
- Lexical Diversity: 1.51111
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15649369', '15167977', '13708014', '12721645', '14661656']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6975842327414364
- 35 USC 102 Novelty (BERT): 0.5194592302145252
- Combined Prediction Score: 0.6797717324887453
- Mean Citation Score: 272.19344199999995
- Max Citation Score: 285.63626
- Similarity Product: 173.54895767986656

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test